BREAST CANCER

During a Case-Based Roundtable® event, Virginia F. Borges, MD, MMSc, discussed treatment selection for a patient with ER+, HER2 0 metastatic breast cancer and a PIK3CA mutation.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard chemotherapy in patients with advanced breast cancer.

In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer.

In a phase 2 trial, datopotamab deruxtecan plus durvalumab achieved a 50% overall pathologic complete response rate in patients with high-risk HER2-negative breast cancer.

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

During a Case-Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment toxicity would affect therapy given to patients with triple-positive breast cancer in the second article of a 2-part series.

The phase 3 study will investigate fezolinetant for vasomotor symptoms in patients receiving adjuvant endocrine therapy.

During a Case-Based Roundtable® event, Ian Krop, MD, PhD, discussed the use of chemotherapy in patients with HER2- and hormone receptor–positive metastatic breast cancer in combination with trastuzumab.

During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.

Yeon Hee Park, MD, discusses the unmet needs in among premenopausal patients with metastatic breast cancer.

In an interview with Targeted Oncology, Hope S. Rugo, MD, FASCO, discussed data from the ELEVATE trial of elacestrant combinations in ER-positive/HER2-negative metastatic breast cancer.

The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.

Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.

At the ASCO Annual Meeting, Asal Pilehvari, PhD, and colleagues presented a study evaluating the financial benefit of adding a CDK 4/6 inhibitor to hormone therapy for women with metastatic estrogen receptor-positive breast cancer in community settings.

Ali Duffens, MD, discusses the relative effectiveness of different detection modalities in identifying breast cancer recurrences.

Erin E. Hahn, PhD, MPH, discussed the findings and implications of a retrospective study exploring breast cancer surveillance in pre- and post-COVID periods.

Pierfranco Conte, MD, discusses findings and implications of the A-BRAVE study.

A study suggests a PIK3CA mutation and blood tests before and after treatment may predict response to alisertib in HR+/HER2–metastatic breast cancer.

Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.

Patients treated with hormone-modulating therapy for breast cancer had a reduced risk of developing Alzheimer disease or dementia compared with patients treated with other agents.

During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.

During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.

Laura Huppert, MD, discussed a retrospective study exploring the sequential use of antibody-drug conjugates for the treatment of HER2-low metastatic breast cancer.

During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer.